TwoStep Therapeutics
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.
$62.5MSeries A
Role not disclosedActivity from announced rounds
Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.
TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.